Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with products approved by the U.S. Food and Drug Administration for the treatment of attention deficit hyperactivity disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (KYE), a private company headquartered in Mississauga, Ontario and focused on the Canadian market, announced that they have entered into an agreement whereby KYE received exclusive rights to commercialize Tris’ FDA-approved ADHD product portfolio in Canada. Under the terms of this agreement, KYE will also handle all ongoing Canadian regulatory activities for the products. Financial terms of the agreement were not disclosed.
Doug Reynolds, president of KYE, explained that Tris’ products have the potential to address a void that exists in the treatment of ADHD. Additionally, according to Mr. Reynolds, KYE’s solutions allow for improved dosing customization and can better assist in finding the optimal dose for an individual.
Tris Pharma is a New Jersey-based specialty pharmaceutical company focused on the development and commercialization of innovative medicines that address unmet consumer needs. Tris has used its innovative LiquiXR technology platform to develop its portfolio of differentiated solid and liquid ADHD products, which it markets in the United States using its pediatric and CNS-focused sales force. The company has leveraged its technology platform to establish a robust product pipeline as well as numerous mutually value-adding development partnerships.
KYE Pharmaceuticals is a private company headquartered in Canada focused on bringing medications to the Canadian market which fulfill clinically significant and unmet needs. KYE has licensed many innovative products and aims to bring unique value to its partners, Canadian health care professionals, and clients.
This was reported by Tris Pharma on July 9, 2020.
Contact information: Tris Pharma, 2031 US Highway 130, Monmouth Junction, New Jersey 08852; 732-940-2800; Website: www.trispharma.com
Contact information: KYE Pharmaceuticals Inc., 2233 Argentia Road, Suites 302 & 302A, Mississauga, Ontario, L5N 2X7; Website: https://kyepharma.com